西蒙顾和：2025早期药物开发中的战略适应症选择：最大化药物全生命周期价值研究报告（英文版）（20页）.pdf

1、simon-Dr.Simone SeiterKevin BaruzziStrategic indication-selection in early-stage drug development to maximize a drugs lifetime value 2IntroductionImagine your organization has developed a groundbreaking innovation in its early stages,offering multiple potential applications across diverse fields due

2、 to its unique characteristics.However,with limited funding,not all promising avenues can be explored at once.Making the right strategic decisions is essential to advancing the innovation efficiently and maximizing its value for the organization.At this stage,with limited and varied scientific evide

3、nce,emerging biopharmaceutical companies must make sound,objective decisions.Executive management often faces considerable uncertainty in the available data,compounded by personal biases from key stakeholders or influential opinion leaders.Despite these challenges,effective strategic decision-making

4、 at this point is critical.How can management overcome these obstacles?Whats needed is an objective assessment approach that can manage information uncertainty,minimize stakeholder bias,and provide a comprehensive,objective per-spective,ultimately maximizing the value of both the drug and the compan

5、y.In this paper,we present a structured framework designed to help executive management make informed strategic decisions in drug development and lifecycle management.This approach aims to maximize the commercial lifetime value of a drug candidate while offering the flexibility to adapt to specific

6、business circumstances.Since every business situation is unique,tailored strategies are essential to succeed where one-size-fits-all approaches have historically fallen short.Biopharmaceutical companies in the early stages of clinical development are often driven primarily by a scientific focus.This